The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine ...
Dec 8, 2021
0
1
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit ...
Dec 7, 2021
0
9
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all ...
Dec 1, 2021
0
1
A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced ...
Nov 17, 2021
0
6
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients ...
Nov 10, 2021
0
2
Younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis, according to results published in Cancer ...
Nov 3, 2021
0
2
Today, the American Association for Cancer Research (AACR) released the 11th edition of its annual Cancer Progress Report, which underscores how cancer research, largely supported by federal investments in the National Institutes ...
Oct 13, 2021
0
4
In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired resistance to KRAS inhibition, ...
Oct 7, 2021
0
9
In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult (AYA) patients with cancers involving the central nervous system, ...
Oct 7, 2021
0
2
Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with mutated KRAS whose disease had progressed ...
Oct 7, 2021
0
0
